AbbVie sued the federal government over the 340B program, arguing the interpretation of the word “patient” in the program should be revisited. The filing comes as the 340B discount framework remains a focal point for hospitals and manufacturers negotiating rebate structures. The dispute aligns with a broader push-pull around government pricing and access programs, where compliance risk and financial reconciliation complexity shape manufacturer and payer strategies. Industry panels have highlighted concerns about double-dipping risk between 340B discounts and Medicaid rebates for the same patient. Separately, Bristol Myers Squibb described operational steps it took to prepare for Medicare price negotiations under the Inflation Reduction Act maximum fair price program, including assembling a cross-functional board deck process soon after the law took effect.